Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1475-2867

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis ; volume:19 ; number:1 ; day:29 ; month:1 ; year:2019 ; pages:1-12 ; date:12.2019
Cancer cell international ; 19, Heft 1 (29.1.2019), 1-12, 12.2019

Creator: Liu, Gao-Min
Li, Xu-Gang
Zhang, Yao-Min

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12935-019-0738-9

URN: urn:nbn:de:101:1-2019030323001463767183

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Liu, Gao-Min
Li, Xu-Gang
Zhang, Yao-Min
SpringerLink (Online service)

Other Objects (12)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC

Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Thermal ablation—an option in curative treatment of HCC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC

Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Thermal ablation—an option in curative treatment of HCC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC

Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Thermal ablation—an option in curative treatment of HCC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC

Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Thermal ablation—an option in curative treatment of HCC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC

Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Thermal ablation—an option in curative treatment of HCC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC

Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Thermal ablation—an option in curative treatment of HCC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer

Related objects

Reset password